Medicine
Lidocan VII 50 mg/g patch
Lidocan VII 50 mg/g patch is a prescription medicine containing Lidocaine for topical use, marketed by Puretek, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Key facts
- Active ingredient (INN)
- Lidocaine
- Brand
- Lidocan VII
- Strength
- 50 mg/g
- Dosage form
- Patch
- Route
- Topical
- Packs
- 30 pouches
- Marketing authorisation holder
- Puretek
- Manufacturer
- Puretek
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C01BB01 Lidocaine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 June 2023
- Identifiers
- RxCUI 1745091, 2642344DailyMed set ID 1f33d51c-168c-55f2-e063-6394a90a8905NDC 59088-900Application ANDA209190
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 pouch in 1 package / 14 g in 1 pouch | 59088-900-54 | Puretek | 8 August 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 November 1948 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lidocaine 50 mg/g patch.
- Lidocaine 50 mg/g patchAvailable on request—US FDA26 packs
- Lidocaine 50 mg/g patchAvailable on request—US FDA15 packs
- Lidocan III 50 mg/g patchAvailable on requestPuretekUS FDA1 pack
- Lidocan IV 50 mg/g patchAvailable on requestPuretekUS FDA1 pack
- Lidocan V 50 mg/g patchAvailable on requestPuretekUS FDA1 pack
- Lidocan VI 50 mg/g patchAvailable on requestPuretekUS FDA1 pack
Other strengths and forms of Lidocaine
Clinical summary
Lidocaine is an amide local anesthetic. It is available as injection, ointment and patches for infiltration, perineural and topical use. MedsAcross supplies Lidocaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LidocaineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Xylocaine prescribing information (Fresenius Kabi) · U.S. National Library of Medicine, DailyMed
Need Lidocan VII 50 mg/g patch for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.